胶质母细胞瘤假性进展:放射病理组学与弥散灌注成像对比
本研究回顾性分析UCSD-PTGBM公开数据集中130例胶质母细胞瘤成人患者的171次MR影像(139次真性进展,32次假性进展),比较放射病理组学细胞密度图与高级弥散灌注指标鉴别真性进展与假性进展的效能。结果显示RPM Cell图在所有时间点的AUC为0.827,显著优于其他影像特征(均<0.687)。
要点
- 放射病理组学细胞密度图(RPM Cell)无需额外对比剂或扫描时间即可生成。
- RPM Cell鉴别真性进展与假性进展的AUC达0.827,优于rCBV、ADC等常规高级影像指标。
- 增强区域内RPM Cell值升高提示真性进展的可能性更大。
核心结论
- RPM Cell图在鉴别胶质母细胞瘤真性进展与假性进展方面显著优于传统灌注和弥散指标(AUC=0.827,p=0.006)。
- RPM Cell是一种无需额外对比剂或扫描时间的非侵入性肿瘤微环境评估工具。
研究设计与样本
- 回顾性单中心研究,使用UCSD-PTGBM公开数据集,纳入130例胶质母细胞瘤成人患者的171次MR影像。
- 参考标准为临床随访确认真性进展139次、假性进展32次。
- 利用常规序列(T1、T1C、FLAIR、ADC)生成放射病理组学细胞密度图(RPM Cell)和细胞外液密度图(RPM ECF)。
- 对照指标包括灌注参数(rCBV、CBF、MTT)和限制谱成像弥散参数(Free、Hindered、Cell)。
- 统计分析采用Pearson相关、混合效应模型及ROC分析,用DeLong检验比较AUC差异。
关键影像表现/征象
- RPM Cell在增强区域内真性进展与假性进展间存在显著差异(B=5.71,p<0.001)。
- RSI Cell在增强区域内真性进展与假性进展间亦存在差异(B=2.54,p=0.01)。
- RPM Cell在所有时间点鉴别真性进展与假性进展的AUC为0.827,其他影像特征AUC均低于0.687。
诊断标准与关键数值
- RPM Cell鉴别真性进展与假性进展的AUC为0.827(所有时间点)。
- 除RPM Cell外,其他弥散和灌注指标的AUC均低于0.687。
临床应用与阅片要点
- 对于放化疗后出现强化增大的胶质母细胞瘤患者,可借助RPM Cell图辅助判断是否为真性进展。
- RPM Cell图基于常规MR序列重建,临床推广不需要额外扫描时间或对比剂注射。
- 阅片时如增强区域RPM Cell值增高,应提高对真性进展的警惕。
局限性
- 研究为回顾性单中心设计,使用公开数据集,缺乏外部验证。
- 假性进展样本量仅32次,真性进展与假性进展比例不平衡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
INTRODUCTION: Glioblastoma is an aggressive brain tumor with poor survival rates and nearly universal recurrence. Magnetic resonance (MR) imaging obtained after radiation and chemotherapy treatment often shows "pseudoprogression" (PsP), or contrast enhancement that mimics tumor growth. However, this does not indicate actual disease progression. This study compared the efficacy of a previously developed radio-pathomic mapping model for discriminating between true progression (TP) and PsP relative to advanced diffusion and perfusion metrics.
MATERIALS AND METHODS: This retrospective study utilized the UCSD-PTGBM single-site public dataset comprised of 171 MR imaging sessions (139 TP and 32 PsP) from 130 adult patients following initial biopsy or resection. Radio-pathomic maps of cell density (RPM Cell) and extracellular fluid density (RPM ECF) from a previously-established methodology were created using conventional imaging data (e.g., T1, T1C, FLAIR, ADC) from the public UCSD dataset. These maps were then compared to perfusion (rCBV, CBF, MTT) and restricted spectrum imaging (RSI) diffusion (Free, Hindered, Cell) features to assess differences between TP and PsP within regions of contrast enhancement. Statistical analyses involved Pearson correlation coefficients, mixed effect models, and receiver operator characteristic (ROC) analysis with area under the curve (AUC) used to evaluate performance at the first and all timepoints, using DeLong's tests to confirm significance.
RESULTS: RPM Cell significantly (p=0.006) outperformed other imaging features in discriminating TP from PsP (AUC=0.827 vs. <0.687 for alternatives, across all timepoints). Features that differed between patients with TP and PsP included RPM Cell (B=5.71, p<0.001) and RSI Cell (B=2.54, p=0.01).
CONCLUSION: RPM Cell shows promise as a novel, accessible marker for detecting tumor recurrence. These cell density maps outperform current advanced imaging techniques in distinguishing true tumor progression from PsP in a retrospective single-site dataset of glioblastoma patients, potentially offering clinicians valuable insights into the tumor microenvironment through a non-invasive modality without requiring additional contrast agents or scan time.
引用
- Reecher, Duenweg, Lowman, et al. A Comparison of Radio-Pathomic, Diffusion, and Perfusion Imaging Features for Identifying Pseudoprogression in Glioblastoma. AJNR Am J Neuroradiol. 2026. PMID: 42567711. doi:10.3174/ajnr.A9574
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。